Mae (Clinics/Outpatient Services) key facts
as of Oct 2026- Provider of maternal health services intended to increase access to doula care and address disparities in outcomes.
- Mae (Clinics/Outpatient Services) is valued at approximately $39.0M as of Oct 2026 (last reported valuation).
- It has raised $10.3M; the latest was Later Stage VC ($2.9M) in Oct 2025.
- Notable investors include MassChallenge, Joyance Partners, Founders Factory, MBX Capital, Impact Engine — 19 tracked in total.
- Status: Privately Held (backing).
Mae (Clinics/Outpatient Services)'s last reported valuation, Oct 2025. Nothing priced has surfaced since.
- ·The complete investor list: 19 names
- ·Watch Mae (Clinics/Outpatient Services): the Monday email on marks, rounds and moves
Mae (Clinics/Outpatient Services) funding rounds
No funding rounds for Mae (Clinics/Outpatient Services) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Mae (Clinics/Outpatient Services)
19+Membership and data by Private Market View
Mae (Clinics/Outpatient Services) valuation
Mae (Clinics/Outpatient Services)'s last reported valuation was $39 million in Oct 2025. No priced round, secondary trade or fund mark has surfaced since.
Mae (Clinics/Outpatient Services) investors
19 investors are on record for Mae (Clinics/Outpatient Services), including MassChallenge, Joyance Partners, Founders Factory and MBX Capital.
About Mae (Clinics/Outpatient Services)
Provider of maternal health services intended to increase access to doula care and address disparities in outcomes. The company offers tailored support, digital coordination, and community-based care, enabling Medicaid and individual plan members to navigate pregnancy with consistent, informed guidance.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2020
- Employees
- 31
- Website
- meetmae.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.